Effect of selegiline on cognitive
functions in Parkinson's disease 

Dixit SN, Behari M, Ahuja GK

Department of Neurology, 
All India Institute of Medical Sciences, New Delhi
J Assoc Physicians India 1999 Aug;47(8):784-6


BACKGROUND: Selegiline hydrochloride, a selective MAO-B inhibitor is known to improve motor functions in Parkinson's disease (PD).  The present study was undertaken to study the effect of selegiline on memory and intelligence of PD patients. 

MATERIAL AND METHOD: Thirty two patients of PD were divided in two groups: selegiline group (n = 17) received 10 mg selegiline per day and control group (n = 15) did not receive selegiline. Patients receiving trihexyphenidyl and selegiline were excluded.  All other treatment remained unchanged.  All patients were examined at baseline and after three months for change in UPDRS score, WAIS score, memory test and P300. 

RESULTS: Patients in selegiline group had less severe disease (UPDRS score 24.11 14.07) as compared to controls (UPDRS score 40.53 18.52).  There was significant improvement in UPDRS score (p < 0.05), WAIS (p < 0.001) and memory (p < 0.001) in selegiline group. In the control group there was a significant prolongation of P300 latency (p < 0.05). 

CONCLUSION: The study suggests that selegiline improves memory functions and intelligence in PD patients in addition to motor functions.  It also prevents prolongation of P300 latency which is a marker of cognitive function.

Parkinson's research / abstracts

 1.    Deprenyl  effect on cognitive functions in early Parkinson's 
Deprenyl  depression in Parkinson's disease
Deprenyl  stimulates biosynthesis of cytokines interleukin-1 & 6
 4.    Deprenyl  effect of MAO-B inhibitors on MPP+ toxicity
 5.    Deprenyl  modulates the decline of the dopamineric system
 6.    Deprenyl 
possible mechanisms of action in Parkinson's 
7.    Deprenyl  pharmacological basis of the beneficial effects
Deprenyl  improves visuo-motor control in early Parkinsonism
Deprenyl  delays disability in Parkinsonian patients
Deprenyl  management of early Parkinson's disease
Deprenyl  delays the onset of disability in Parkinsonian patients
Deprenyl  and tocopherol antioxidative therapy of Parkinsonism